Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)
Conditions
- Chronic Lymphocytic Leukemia
- Indolent Non-Hodgkin Lymphoma
- Follicular Lymphoma
- Small Lymphocytic Lymphoma
- Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)
- Marginal Zone Lymphoma
Interventions
Sponsor
Gilead Sciences